Secondary glaucoma after bevacizumab injection in Type-1 retinopathy of prematurity
Purpose: The authors report three separate cases of type 1 retinopathy of prematurity (ROP) treated with intravitreal bevacizumab before, or at 34 weeks postmenstrual age (PMA), with subsequent development of secondary glaucoma. Observations: All three cases involve patients born ≤24 weeks and meeti...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993624001415 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850251625487138816 |
|---|---|
| author | Anthony A. Jones Jacob S. Martin Annette L. Giangiacomo Deborah M. Costakos |
| author_facet | Anthony A. Jones Jacob S. Martin Annette L. Giangiacomo Deborah M. Costakos |
| author_sort | Anthony A. Jones |
| collection | DOAJ |
| description | Purpose: The authors report three separate cases of type 1 retinopathy of prematurity (ROP) treated with intravitreal bevacizumab before, or at 34 weeks postmenstrual age (PMA), with subsequent development of secondary glaucoma. Observations: All three cases involve patients born ≤24 weeks and meeting the American Academy of Pediatrics criteria for ROP screening. Prior to treatment, each patient was noted to have normal anterior chamber structures with no signs of glaucoma. Each patient developed type 1 ROP and was treated with intravitreal bevacizumab, which was administered at or before 34 weeks PMA. Following the administration of intravitreal anti-vascular endothelial growth factor (VEGF), each patient developed a suspected open-angle glaucoma (OAG) within an approximate 4-week time frame. In these cases, the presentation of glaucoma differed from those that have been previously reported in the literature. Conclusion and importance: Based on similar timing of glaucoma development following intravitreal bevacizumab injections, we hypothesize that the administration of anti-VEGF agents to very premature infants (≤24 weeks) at or before 34 weeks PMA, may predispose them to the development of secondary glaucoma through an unknown and possibly novel pathway. |
| format | Article |
| id | doaj-art-e6a63e9b1eab438fa84fdcbd3cb2fbd7 |
| institution | OA Journals |
| issn | 2451-9936 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Ophthalmology Case Reports |
| spelling | doaj-art-e6a63e9b1eab438fa84fdcbd3cb2fbd72025-08-20T01:57:51ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362024-12-013610213110.1016/j.ajoc.2024.102131Secondary glaucoma after bevacizumab injection in Type-1 retinopathy of prematurityAnthony A. Jones0Jacob S. Martin1Annette L. Giangiacomo2Deborah M. Costakos3Department of Ophthalmology, Medical College of Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI 53226, USA; Department of Pediatric Ophthalmology, Children's Hospital Milwaukee, 8915 W Connell Ct, Milwaukee, WI 53226, USA; Corresponding author. Medical College of Wisconsin 8701 W Watertown Plank Rd. Milwaukee, WI, 53226, USA.Department of Ophthalmology, Medical College of Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI 53226, USA; Department of Pediatric Ophthalmology, Children's Hospital Milwaukee, 8915 W Connell Ct, Milwaukee, WI 53226, USADepartment of Ophthalmology, Medical College of Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI 53226, USA; Department of Pediatric Ophthalmology, Children's Hospital Milwaukee, 8915 W Connell Ct, Milwaukee, WI 53226, USADepartment of Ophthalmology, Medical College of Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI 53226, USA; Department of Pediatric Ophthalmology, Children's Hospital Milwaukee, 8915 W Connell Ct, Milwaukee, WI 53226, USAPurpose: The authors report three separate cases of type 1 retinopathy of prematurity (ROP) treated with intravitreal bevacizumab before, or at 34 weeks postmenstrual age (PMA), with subsequent development of secondary glaucoma. Observations: All three cases involve patients born ≤24 weeks and meeting the American Academy of Pediatrics criteria for ROP screening. Prior to treatment, each patient was noted to have normal anterior chamber structures with no signs of glaucoma. Each patient developed type 1 ROP and was treated with intravitreal bevacizumab, which was administered at or before 34 weeks PMA. Following the administration of intravitreal anti-vascular endothelial growth factor (VEGF), each patient developed a suspected open-angle glaucoma (OAG) within an approximate 4-week time frame. In these cases, the presentation of glaucoma differed from those that have been previously reported in the literature. Conclusion and importance: Based on similar timing of glaucoma development following intravitreal bevacizumab injections, we hypothesize that the administration of anti-VEGF agents to very premature infants (≤24 weeks) at or before 34 weeks PMA, may predispose them to the development of secondary glaucoma through an unknown and possibly novel pathway.http://www.sciencedirect.com/science/article/pii/S2451993624001415AvastinBevacizumabSecondary glaucomaRetinopathy of prematurity |
| spellingShingle | Anthony A. Jones Jacob S. Martin Annette L. Giangiacomo Deborah M. Costakos Secondary glaucoma after bevacizumab injection in Type-1 retinopathy of prematurity American Journal of Ophthalmology Case Reports Avastin Bevacizumab Secondary glaucoma Retinopathy of prematurity |
| title | Secondary glaucoma after bevacizumab injection in Type-1 retinopathy of prematurity |
| title_full | Secondary glaucoma after bevacizumab injection in Type-1 retinopathy of prematurity |
| title_fullStr | Secondary glaucoma after bevacizumab injection in Type-1 retinopathy of prematurity |
| title_full_unstemmed | Secondary glaucoma after bevacizumab injection in Type-1 retinopathy of prematurity |
| title_short | Secondary glaucoma after bevacizumab injection in Type-1 retinopathy of prematurity |
| title_sort | secondary glaucoma after bevacizumab injection in type 1 retinopathy of prematurity |
| topic | Avastin Bevacizumab Secondary glaucoma Retinopathy of prematurity |
| url | http://www.sciencedirect.com/science/article/pii/S2451993624001415 |
| work_keys_str_mv | AT anthonyajones secondaryglaucomaafterbevacizumabinjectionintype1retinopathyofprematurity AT jacobsmartin secondaryglaucomaafterbevacizumabinjectionintype1retinopathyofprematurity AT annettelgiangiacomo secondaryglaucomaafterbevacizumabinjectionintype1retinopathyofprematurity AT deborahmcostakos secondaryglaucomaafterbevacizumabinjectionintype1retinopathyofprematurity |